



Oncology Condition Management Program Overview

Program to enhance cancer care and improve quality of care, experience, and affordability for your employees diagnosed with cancer.

Cancer diagnoses continue to rise, thrusting patients into a costly, complex, and confusing oncology care journey.

INCREASING INCIDENCE RATES

New cancer diagnoses continue to rise nationwide, with new cases in 2025 projected to top


2 million

Numbers are highest in California, with new cases projected to reach

200,000¹

SKYROCKETING COSTS

Global Oncology Drug Spend
(in billions)²



QUESTIONABLE VALUE

68%

of drug approvals did not increase overall survival (2006 – 2023)³

FINANCIAL BURDEN

~50%

cancer patients have medical debt related to their cancer, leading to cascading financial impact⁴

1. American Cancer Society (2025). Cancer Facts and Figures 2025. 2. IQVIA. (2024). Global Oncology Trends 2024: Outlook to 2028. IQVIA. 3. The US FDA's cancer drug approval process is broken and needs audit (2024)

Our approach simplifies the journey and supports members to improve quality of care, experience, and affordability.

ACCELERATE TREATMENT REVIEW	We streamline the treatment review process for providers, reducing time to treatment for members.
PRIORITIZE MEMBER NEEDS	We engage members to guide them on an optimal care journey, supporting member and caregiver needs and wishes to improve experience and quality of life.
IMPROVE CLINICAL DECISION MAKING	We ensure all members receive the right treatment by guiding oncologists to the highest-value option and avoiding therapies with minimal clinical benefit.

PROGRAM IMPACT

100%
shift to same or
higher-quality care

3-4x savings
in addition to quality improvement

95%
member and caregiver
satisfaction score

Accelerate treatment review

OBJECTIVE	Streamline the treatment review process for providers, reducing time to treatment for members.
-----------	------------------------------------------------------------------------------------------------

APPROACHES



Algorithm-driven auto-approvals



Streamlined data collection



Automatic opportunity identification



Specialty-matched peer-to-peers

IMPACT METRICS

<2%
average recommended adverse determination rate¹

>99%
treatment review turnaround time compliance²

1. 2024 Evolent oncology prior authorization requests; 2. Evolent internal data analysis; 2. 2024 Evolent internal data

Prioritize member needs

OBJECTIVE	Guide members through optimal care journey, supporting member and caregiver needs and wishes to improve experience and quality of life.
-----------	-----------------------------------------------------------------------------------------------------------------------------------------

APPROACHES



Practice engagement for warm referrals and care coordination



Multidisciplinary care team



Care management member app



Goal-concordant care support

IMPACT METRICS

\$400-\$500

Avg Part A spend reduction PEMPM compared to non-engaged (\$2,722 vs. \$2,255)¹

94%


members agreed or strongly agreed that the navigator helped them get the resources they needed²

1) Based on internal and partner analysis of navigation pilot between 11/2023 and 10/2024
2) Per patient/caregiver experience surveys conducted between Apr – May 2024

Improve clinical decision making

OBJECTIVE	Guide oncologists to the highest-value option and avoiding therapies with minimal clinical benefit.
-----------	-----------------------------------------------------------------------------------------------------

Further optimizing NCCN Pathways...



...improves quality and lowers cost

HER2+ Metastatic Breast Cancer

Average Cost (\$k) Per Treatment¹

